The thesis

Johnson & Johnson operates in the healthcare sector with a gross margin of 70.45% and revenue growth of 6.6% YoY. The company's conviction score is 25, indicating medium conviction. Analyst consensus is BUY, but a P/E of 30.8x raises valuation concerns. The company's high margins and growth slowdown make it vulnerable to drug pricing policy shocks.

Why now

The recent inflation fears and S&P 500 slip make the high valuation of Johnson & Johnson more concerning. The 6.6% YoY revenue growth slowdown heightens the risk.

What to watch

Upcoming revenue reports will show if Johnson & Johnson's 6.6% YoY growth is sustainable. Changes in drug pricing policy or major trial results over the next quarter will be critical indicators.

Key risks

Drug pricing policy changes and trial failures are recurring shocks that could impact Johnson & Johnson's revenue. High valuation (P/E 30.8x) leaves little room for error, making the stock vulnerable to downside risk.

Theme exposure